NCT00522795

Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)

BrUOG-E-215-Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Brown University · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001

Detailed description

32 patients with esophageal or gastroesophageal junction cancer will receive Radiation:50.4 Gy at 180cGy fraction/day for 28 treatments and Paclitaxel Poliglumex (PPX) and Cisplatin weekly times 6 followed by surgery.

Conditions

• Esophageal Cancer

Interventions

Type	Name	Description
DRUG	PPX with cisplatin and radiation	weekly IV treatment of Paclitaxel Poliglumex and Cisplatin for 6 weeks

Timeline

• Start date: 2007-08-01
• Primary completion: 2010-02-01
• Completion: 2010-04-01
• First posted: 2007-08-30
• Last updated: 2020-02-17
• Results posted: 2013-08-22

Locations

1 site across 1 country: United States